AMGEN [ Biotecnologia ]

5 respuestas
AMGEN [ Biotecnologia ]
AMGEN [ Biotecnologia ]

AMGEN [ Biotecnologia ]

Ahora mismo esta cayendo, y llevo semanas siguiendo esta empresa.

Alguien la lleva en su cartera a largo? Parece buena empresa.


Re: AMGEN [ Biotecnologia ]

Yo la llevo. Me gusta que es una Farma con producción sobre todo de tratamsientos biológicos (basados en anticuerpos) que creo que en el futuro tendrán muchas ventajas respecto a los tratamientos convencionales basados en compuestos orgánicos sencillos. Los fundamentales son buenos, es el tipo de empresa que me gusta, con poca deuda y márgenes buenos. Además con un PER razonable. La pega es que los ingresos están un poco estancados, en gran medida porque el que iba a ser su producto estrella, evolucumab (repatha), un tratamiento biológico para el colesterol, ha resultado no ser tan beneficioso como se esperaba y para colmo a la competencia, Praluent (de Sanofi) le ha ido algo mejor, y por otro lado porque la legislación sobre biosimilares está cambiando. Pero creo que todo ello no deja de ser ruido de mercado, la empresa tiene cada vez más diversificación de productos y acabará por mejorar sus ingresos.

Por cierto, otra gran empresa del ámbito de la sanidad es Fresenius. Aunque es un negocio más amplio y variado (relacionado sobre todo con la hemodiálisis, pero también ofrecen servicios sanitarios; son indirectamente dueños de Quiron, como ejemplo). Resulta que Fresenius también empezará a comerciar biosimilares (versión “medicamentos genéricos” de las terapias biológicas).


Re: AMGEN [ Biotecnologia ]

Yo nunca participo, ni recomiendo, el mercado internacional.- Saludos.

El problema fundamental de la Bolsa es la corrupción y manipulación.


Re: AMGEN [ Biotecnologia ]

Joder, pues espero que no tengas una cartera a largo en el ibex, porque la debes de tener mas roja que el culo de un mono.


Re: AMGEN [ Biotecnologia ]

Yo la verdad es que estoy un poco arrepentido del mercado español (10%), cobran menos comisiones y tributaciones, pero no le he visto subir en decadas. En cambio el USA (50%) no me ha dado mas que satisfacciones, es mas caro pero no ha dejado de subir hasta ahora. Sigo en los dos, ya no se hacer otra cosa, pero los veo un poco chungos, tengo confianza en el largo plazo. La liquidez euro (40%) tampoco me gusta, me da el 0%. ¡Saludos!


Amgen compra Five Prime Therapeutics

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio.
  • Five Prime's lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer. Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer, as well as other solid tumors.
  • The bemarituzumab Phase 2 FIGHT trial demonstrated clinically meaningful improvements in progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) in the frontline treatment of patients with advanced gastric or GEJ cancer. Additional analysis showed a positive correlation between efficacy and expression of FGFR2b on tumor cells, confirming both the importance of the FGFR2b target and the activity of bemarituzumab against this target.
  • This correlation suggests that FGFR2b could play a role in other epithelial cancers, including lung, breast, ovarian and other cancers. 
  • The acquisition of Five Prime also supports Amgen's international expansion strategy. Gastric cancer is one of the world's most common forms of cancer and is particularly prevalent in the Asia-Pacific region, where Amgen expects to generate significant volume growth in the coming years. Amgen plans to leverage its presence in Japan and other Asia-Pacific markets to maximize bemarituzumab's potential. In addition, as part of this transaction, Amgen will receive a royalty percentage on future net sales in Greater China ranging from the high teens to the low twenties from a pre-existing co-development and commercialization agreement between Five Prime and Zai Lab (Shanghai) Co., Ltd.
  • Five Prime's additional innovative pipeline programs complement Amgen's efforts to bring meaningful therapies to oncology patients. 
"The acquisition of Five Prime offers a compelling opportunity for Amgen to strengthen our oncology portfolio with a promising late-stage, first-in-class global asset to treat gastric cancer," said Robert A. Bradway, chairman and chief executive officer at Amgen. "We look forward to welcoming the Five Prime team to Amgen and working with them to leverage our best-in-class monoclonal antibody manufacturing capabilities to supply additional clinical materials, as well as expanded production quantities, to realize the full potential of bemarituzumab for even more patients around the world as quickly as possible."
"This is an exciting day for patients who may one day benefit from the promise of bemaritizumab and our full pipeline. I'm so proud of the Five Prime team and the science we've pioneered," said Tom Civik, president and chief executive officer of Five Prime. "We see tremendous complementarity between the two companies. Amgen has global reach, world-class resources, and they share our deep passion for science and commitment to patients.  I have full confidence that Amgen is the right company to work with us to bring our innovative cancer treatments to patients and to achieve our mission to rewrite cancer." 
Transaction Terms
Under the terms of the merger agreement, which was approved by the Boards of Directors of both companies, Amgen will commence a tender offer to acquire all of the outstanding shares of Five Prime's common stock for $38.00 per share in cash. Following the completion of the tender offer, a wholly-owned subsidiary of Amgen will merge with Five Prime and shares of Five Prime that have not been tendered and purchased in the tender offer will be converted into the right to receive the same price per share in cash as paid in the tender offer (other than shares held by stockholders who properly demand and perfect appraisal rights under Delaware law).
The transaction is expected to close by the end of the second quarter and is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Five Prime's common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Amgen reaffirmed its full-year outlook with Revenue guidance of $25.8 to $26.6 billion and non-GAAP EPS guidance of $16.00-$17.00.
Goldman Sachs acted as financial advisor to Amgen and Sullivan & Cromwell LLP as its legal advisor. Lazard acted as financial advisor to Five Prime and Cooley LLP as its legal advisor.
Amgen Webcast Investor Call
Amgen will host a webcast call for the investment community on Thursday, March 4, 2021, at 10:30 a.m. EST. Peter H. Griffith, executive vice president and chief financial officer, David M. Reese, M.D., executive vice president of Research and Development, and Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will participate. 
Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website,, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 
About FGFR2b
The fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway is implicated in the development and growth of cancer cells. FGFR2b is a splice variant of FGFR2 which can be found in tumors of epithelial origin. Data from the FIGHT trial suggests that approximately 30 percent of patients with non-HER2 positive gastroesophageal cancers overexpress FGFR2b.1 FGFR2b has also been shown to be overexpressed in numerous other cancers, including lung, breast, ovarian and other cancers.
About Bemarituzumab
Bemarituzumab (anti-FGFR2b) is a first-in-class targeted antibody that blocks fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pro-tumor signaling pathways and potentially slowing cancer progression. Five Prime Therapeutics granted an exclusive license to Zai Lab Limited to develop and commercialize bemarituzumab in Greater China, and Zai Lab collaborated with Five Prime Therapeutics on the Phase 2 FIGHT trial in Greater China.
About the FIGHT Trial
The FIGHT study was a randomized, placebo controlled trial that evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus placebo plus chemotherapy in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), non HER2 positive frontline advanced gastric or GEJ cancer. The trial enrolled 155 patients in 15 countries across Asia, the European Union, and the United States, with 77 patients randomized to the bemarituzumab arm and 78 patients to the placebo arm.
About Gastric Cancer and GEJ Cancer
Gastric cancer, also known as stomach cancer, is the third most common cause of cancer death worldwide and, excluding non-melanoma skin cancer, the fifth most common cancer worldwide, with over 1,000,000 new cases diagnosed each year.2 For HER2 negative patients, frontline therapy available today is the same systemic chemotherapy available since the 1990s.3,4
About  Five Prime Therapeutics
Five Prime Therapeutics is a clinical stage biotechnology company relentlessly focused on rewriting cancer. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. This vision is what defines us and guides our research, clinical development and partnerships. To build a better tomorrow for people with cancer, we are teaming up with patients, physicians, scientists, and industry partners to make a meaningful difference in patients' lives. Five Prime collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development.

Cookies en

Utilizamos cookies propias y de terceros con finalidades analíticas y para mostrarte publicidad relacionada con tus preferencias a partir de tus hábitos de navegación y tu perfil. Puedes configurar o rechazar las cookies haciendo click en “Configuración de cookies”. También puedes aceptar todas las cookies pulsando el botón “Aceptar”. Para más información puedes visitar nuestra política de cookies.